Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection

JAMA - Journal of the American Medical Association

Volumn 313, Issue 17, 2015, Pages 1728-1735

  Poordad, Fred ^a   Sievert, William ^b   Mollison, Lindsay ^c   Bennett, Michael ^d   Tse, Edmund ^e   Bräu, Norbert ^f,g   Levin, James ^h   Sepe, Thomas ⁱ   Lee, Samuel S ^j   Angus, Peter ^k   Conway, Brian ^l   Pol, Stanislas ^m   Boyer, Nathalie ⁿ   Bronowicki, Jean Pierre ^o   Jacobson, Ira ^p   Muir, Andrew J ^q   Reddy, K Rajender ^r   Tam, Edward ^s   Ortiz Lasanta, Grisell ^t   De Lédinghen, Victor ^u   Sulkowski, Mark ^v   Boparai, Navdeep ^w   McPhee, Fiona ^w   Hughes, Eric ^w   Swenson, E Scott ^w   Yin, Philip D ^w   more..

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Medical Associates Research Group   (United States)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Dean Foundation   (United States)

ⁱ University Gastroenterology   (United States)

^j UNIVERSITY OF CALGARY   (Canada)

^k AUSTIN HOSPITAL   (Australia)

^l VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

^m UNIVERSITÉ PARIS DESCARTES   (France)

ⁿ BEAUJON HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF NANCY   (France)

^p WEILL CORNELL MEDICAL COLLEGE   (United States)

^q DUKE UNIVERSITY MEDICAL CENTER   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s LAIR Centre   (Canada)

^t Department of Hematology and Oncology   (Puerto Rico)

^u HAUT LÉVÊQUE HOSPITAL   (France)

^v JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BILIRUBIN; CREATINE KINASE; HEMOGLOBIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; TRIACYLGLYCEROL LIPASE; VIRUS RNA; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ANTIVIRUS AGENT; ASUNAPREVIR; BENZAZEPINE DERIVATIVE; BMS-790052; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; BILIRUBIN BLOOD LEVEL; CANADA; CAUCASIAN; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FRANCE; GENE; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERTRANSAMINASEMIA; IL28B GENE; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; PATIENT COMPLIANCE; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RELAPSE; RHABDOMYOLYSIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNITED STATES; VIRUS DETECTION; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BENZAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INDOLES; ISOQUINOLINES; MALE; MIDDLE AGED; SULFONAMIDES;

EID: 84929207643     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.3860     Document Type: Article

References (21)

1. Hepatitis C [factsheet No. 164]. World Health Organization. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed December 12, 2014.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection. Hepatology. 2013;57(4):1333-1342.
3. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes. Hepatology. 2014;59(1):318-327.
4. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013;3(5):514-520.
5. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56(10):5387-5396.
6. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b. Lancet. 2014;384(9954):1597-1605.
7. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146(2):420-429.
8. Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection [published online January 2, 1015]. J Hepatol. doi:10.1016/j.jhep.2014.12.025.
9. Li C, Njouom R, Pépin J, et al. Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1. J Gen Virol. 2013;94(Pt 8):1780-1790.
10. Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
11. Kowdley KV, Gordon SC, Reddy KR, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-1888.
12. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
13. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-1603.
14. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17):1604-1614.
15. Everson GT, Sims KD, Thuluvath PJ, et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. Hepatology. 2013;58(6)(suppl):1377A.
16. Ferenci P, Bernstein D, Lalezari J, et al PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992.
17. Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. doi:10.1001/jama.2015.3868.
18. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083-2091.
19. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216-224.
20. Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60(3):490-499.
21. Bronowicki JP, Pol S, Thuluvath PJ, et al. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther. 2013;18(7):885-893.